Skip to main content
OpenTrials
Completed

NCT Number: NCT02322229

Ocriplasmin for Vitreomacular Traction/Symptomatic Vitreomacular Adhesion

The purpose of this study is to observe the anatomical and functional outcomes of ocriplasmin (JETREA™®) over a 6-month period.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Vitreomacular Traction Vitreomacular Adhesion

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Contact Alcon Laboratories (Australia) for Trial Locations

New South Wales, 2113, Australia

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of VMT/sVMA, with evidence of focal VMT visible on Spectral Domain - Optical Coherence Tomography (SD-OCT).
  • Read, sign, and date an Institutional Review Board/Ethics Committee-approved informed consent form.
  • Willing and able to attend all study visits.
  • Other protocol-specified inclusion criteria may apply.

Exclusion criteria

  • Women of childbearing potential if pregnant, test positive on a urine pregnancy test, intend to become pregnant during the study period, breastfeeding, or not in agreement to use adequate birth control methods to prevent pregnancy throughout the study.
  • Hypersensitivity to ocriplasmin or any of the JETREA™® excipients.
  • Active or suspected intraocular or periocular infection in either eye.
  • Participation in any interventional clinical trial within 30 days prior to baseline.
  • Presence of epiretinal membrane (ERM) over the macula at baseline in the study eye.
  • Broad VMT/VMA > 1500 microns at baseline in the study eye.
  • History of vitrectomy in the study eye.
  • History of laser photocoagulation to the macula in the study eye.
  • Any relevant concomitant ocular condition in the study eye that, in the opinion of the Investigator, could be expected to worsen or require surgical intervention during the study period.
  • Macular hole of > 400 microns diameter in the study eye.
  • High myopia in the study eye.
  • Pseudo-exfoliation, Marfan's syndrome, phacodonesis, or any other finding in the study eye that, in the Investigator's opinion, suggests lens/zonular instability.
  • Aphakia in the study eye.
  • History of retinal detachment in the study eye.
  • Recent ocular surgery or ocular injection in the study eye within the past 90 days (including laser therapy).
  • Proliferative diabetic retinopathy or ischemic retinopathies in the study eye.
  • Retinal vein occlusions in the study eye.
  • Exudative age-related macular degeneration (AMD) in the study eye.
  • Vitreous hemorrhage in the study eye.
  • Other protocol-specified exclusion criteria may apply.

Treatment and study plan

Ocriplasmin 0.125 mg in a 0.1 mL volume

Drug

Other names: JETREA™®

Primary outcomes

  1. Percentage of Subjects With Non-surgical Resolution of Focal VMT/sVMA at Day 28, as Determined by Central Reading Center (CRC) Spectral Domain Optical Coherence Tomography (SD-OCT) Evaluation

    Time frame: Day 28

    Vitreous separation was assessed, by SD-OCT according to CRC OCT image reading, into 1 of 12 categories, where the targeted status of VMA resolution was 7=Vitreous attached only at optic nerve (ON) or at ON and elsewhere, but not attached in macular, 9=Vitreous visible with complete separation and no attachment, and 10=No visible vitreous separation, which needed to be reached without prior vitrectomy. The assessment of resolution of VMT/sVMA was based upon the anatomical resolution of VMA only, i.e. no resolution of the related symptoms was considered. One eye (study eye) contributed to the analysis.

Secondary outcomes

  1. Change From Baseline in Best-corrected Visual Acuity (BCVA) at Distance at Days 7, 28, 90, and 180

    Time frame: Baseline (Day 0), Day 7, Day 28, Day 90, Day 180

    BCVA was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) testing. BCVA was determined as follows: if tested at 4 meters, BCVA=the number of letters read correctly at 4 meters+30; if tested at 1 meter, BCVA=the number of letters read correctly at 1 meter, with 83-84 representing normal vision. BCVA change was defined as a change in letters read from the baseline assessment. A positive change value indicates improvement. One eye (study eye) contributed to the analysis.

  2. Percentage of Subjects With Closure of Macular Hole (MH), at Days 7, 28, 90, and 180 (if Present at Baseline)

    Time frame: Day 7, Day 28, Day 90, Day 180

    The closure of macular hole (a full thickness defect of the retinal tissue involving the anatomical fovea) is defined as a flattened and reattached hole rim along the whole circumference of macular hole. Closure was determined by SD-OCT evaluation and the percentage of subjects tabulated. One eye (study eye) contributed to the analysis.

  3. Percentage of Subjects With Non-surgical Resolution of VMT/sVMA at Days 7, 90, and 180

    Time frame: Baseline (Day 0), Day 7, Day 90, Day 180

    As described in Primary Outcome Measure

  4. Percentage of Subjects Experiencing Pars Plana Vitrectomy (PPV) at Day 180

    Time frame: Day 180

    Pars plana vitrectomy (the surgical removal of vitreous gel from the eye) was captured in Concomitant Ocular Procedures. One eye (study eye) contributed to the analysis.

  5. Change From Baseline in Central Foveal Thickness at Days 28 and 180

    Time frame: Baseline (Day 0), Day 28, Day 180

    Central foveal thickness (CFT) was determined by subtracting the measurements in subretinal fluid (SRF) and retinal pigment epithelium (RPE) elevation and/or subretinal hyper-reflective material (SHRM) from the value in total retinal measurement. The change was defined as a change from baseline values of CFT. One eye (study eye) contributed to the analysis.

Sponsors and collaborators

Lead sponsor

Alcon Research

Industry

Registry information

Official study title

Assessment of Anatomical and Functional Outcomes in Subjects Treated With Ocriplasmin for Vitreomacular Traction/Symptomatic Vitreomacular Adhesion (VMT/sVMA)

Important dates

Study start
2015
Primary completion
2015
Study completion
2016
First posted
Dec 23, 2014
Registry last updated
Aug 21, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.